Skip to content

Study · Non-randomized trial · n = 114 · 2000

3 results

Functional bladder capacity as predictor of response to desmopressin and retention control training in monosymptomatic nocturnal enuresis.

Hamano S, Yamanishi T, Igarashi T, Ito H, Murakami S

European urology1 Jun 2000Cited by 30 (Europe PMC)

PMID10828674 (opens in a new tab)DOI10.1159/000020224 (opens in a new tab)PepBankPUB-10828674
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In children with enuresis, strong improvement occurred in 21 of 54 (38.9%) with DDAVP versus 14 of 60 (23.3%) with retention training (p = 0.061).

    In plain wordsIn children with enuresis, strong improvement was 38.9% with DDAVP and 23.3% with retention control training (p = 0.061).

    Peptide
    Desmopressin
    Outcome
    IncreaseStrong improvement
    Study

    n = 114

    Comparator
    Retention control training
    Outcome group
    Enuresis · Kidney and urinary
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Measurements

    Patients with strong improvement
    21 patients
    DDAVP group, 54 patients
    Patients with strong improvement
    38.9%
    DDAVP group
    Patients with strong improvement
    14 patients
    retention control training group, 60 patients
    Patients with strong improvement
    23.3%
    retention control training group

    Source sentences

    Summary
    Twenty-one of 54 patients (38.9%) and 14 of 60 patients (23.3%) in the DDAVP group and the RCT group, respectively, achieved strong improvement (p = 0.061).
    1 context sentence
    Summary · context
    A total of 114 children with monosymptomatic nocturnal enuresis, of whom 99 (86.8%) wetted the bed every night, were treated with 1 of the 2 methods: intranasal DDAVP in 54 and RCT in 60 subjects.
  2. 02HumanNon-randomized trialEfficacy outcome

    In children with enuresis, 45 of 54 (reported as 90.0%) with DDAVP versus 35 of 60 (58.3%) with retention training had over 50% fewer wet nights (p = 0.004).

    In plain wordsIn children with enuresis, more DDAVP patients than retention training patients had over 50% fewer wet nights.

    Peptide
    Desmopressin
    Outcome
    IncreaseMore than half decrease in wet nights
    Study

    n = 114

    Comparator
    Retention control training
    Outcome group
    Enuresis · Kidney and urinary
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Measurements

    Patients with more than 50% decrease in wet nights
    45 patients
    DDAVP group, 54 patients
    Patients with more than 50% decrease in wet nights
    90%
    DDAVP group, as reported
    Patients with more than 50% decrease in wet nights
    35 patients
    retention control training group, 60 patients
    Patients with more than 50% decrease in wet nights
    58.3%
    retention control training group

    Source sentences

    Summary
    Forty-five of 54 (90.0%) in the DDAVP and 35 of 60 (58.3%) in the RCT group had a more than 50% decrease in wet nights (p = 0.004).
    1 context sentence
    Summary · context
    A total of 114 children with monosymptomatic nocturnal enuresis, of whom 99 (86.8%) wetted the bed every night, were treated with 1 of the 2 methods: intranasal DDAVP in 54 and RCT in 60 subjects.
  3. 03HumanNon-randomized trialOther

    In children receiving DDAVP, baseline functional bladder capacity was 82+/-22% of predicted in responders versus 56+/-20% in nonresponders (p<0.001).

    In plain wordsIn children receiving DDAVP, response was linked to higher baseline bladder capacity than in nonresponders.

    Peptide
    Desmopressin
    Outcome
    IncreaseBaseline bladder capacity and response
    Study

    n = 54

    Comparator
    DDAVP nonresponders
    Outcome group
    Enuresis · Kidney and urinary
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Measurements

    Baseline functional bladder capacity
    82 % of predicted bladder capacity for age
    DDAVP responders (+/-22)
    Baseline functional bladder capacity
    56 % of predicted bladder capacity for age
    DDAVP nonresponders (+/-20)

    Source sentences

    Summary
    In the DDAVP group, the functional bladder capacities at baseline in responders and nonresponders were 82+/-22% and 56+/-20% of the predicted bladder capacity for their age (p<0.001).
    1 context sentence
    Summary · context
    A total of 114 children with monosymptomatic nocturnal enuresis, of whom 99 (86.8%) wetted the bed every night, were treated with 1 of the 2 methods: intranasal DDAVP in 54 and RCT in 60 subjects.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

RecruitingNot applicableNCT06883851

Effectiveness of Pelvic Floor Muscle Rehabilitation Combined With Desmopressin in Children With Primary Monosymptomatic Nocturnal Enuresis

Bahçeşehir Universityn = 4011 Mar 2025 to est. 30 Aug 2027

Primary Nocturnal Enuresis · Nocturnal Enuresis in Children

Trial pageClinicalTrials.govUpdated 19 Mar 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.